J Cardiovasc Interv.  2023 Oct;2(4):199-208. 10.54912/jci.2023.0004.

Drug-Coated Balloon Treatment for De Novo Coronary Artery Disease

• Her AY
• Kim YH
• Shin ES

• KMID: 2560946
• DOI: http://doi.org/10.54912/jci.2023.0004

Abstract

Although current drug-eluting stents (DES) are considered to be the standard treatment for patients undergoing percutaneous coronary intervention (PCI) with de novo coronary artery disease (CAD), there are some limitations such as restenosis, stent thrombosis or obligatory use of dual antiplatelet therapy (DAPT) with unknown optimal duration and some subgroups of patients still show relatively high adverse event rates after stenting. Drug-coated balloons (DCB) treatment has the concept of leave-nothing-behind and therefore it can be free from stent thrombosis and long-term use of DAPT. It directly delivers an anti-proliferative drug which is coated on a balloon after improving coronary blood flow. For de novo coronary lesions, although more data are needed for the application of DCB treatment, recent reports have suggested that DCB treatment was safe and effective for conditions such as small and large vessel diseases, complex lesions such as bifurcation lesions or multivessel diseases, chronic total occlusion lesions, and others. Therefore, we will discuss the currently available therapeutic strategies for the management of de novo CAD with DCB and the evidence supporting their concurrent use in this review.

Keyword

Drug-eluting stent; Coronary artery disease